Immunotherapies enhance patients’ endogenous immune system function of attacking tumor cells, and are being widely and successfully used in the field of immuno-oncology.
New therapeutic classes and combinations are changing the cancer landscape, bringing the promise of significant patient benefits. But they can complicate trial and commercialization strategies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
